Updated:
Passage BIO, Inc.
Passage BIO, Inc. is a clinical-stage biotechnology firm developing AAV-based gene therapies for rare diseases.
Passage BIO, Inc.
Passage BIO, Inc. was founded as a biotechnology company dedicated to developing gene therapies for patients with rare diseases. The firm's platform utilizes AAV vectors to deliver genetic payloads, with clinical programs addressing conditions like Duchenne muscular dystrophy and Batten disease. Its therapeutics remain in early-stage clinical trials, with no approved products to date. Strategically, Passage BIO focuses on pre-clinical and clinical development, operating a pipeline of wholly-owned candidates and partnerships. The company's asset class mix includes research-stage assets and potential regulatory milestones, though it does not deploy capital as an investment firm. Geographic footprint centers on the United States, with clinical trial sites and research operations located domestically. Passage BIO maintains a lean operational structure typical of early-stage biotechs, with a team size and financial details not publicly disclosed in available sources. No recent operational events from the last 24 months have been verified. The firm may have philanthropic or research collaborations, but these are not confirmed in public records. The structural differentiator for Passage BIO is its pure-play gene therapy focus, which distinguishes it from broader biotech firms. However, without public financial disclosures or verifiable leadership, the firm's architecture remains opaque, limiting assessment of its investment or ownership structure.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Who runs investment decisions at Passage BIO?
Passage BIO is a biotechnology company, not an investment firm, so no investment decision-makers are disclosed. Leadership details are not publicly available in standard sources. The firm likely has a scientific advisory board for R&D direction.
Is Passage BIO structured as a family office or asset manager?
No. Passage BIO, Inc. operates as a for-profit biotechnology corporation focused on therapeutic development. It is not organized as a family office, investment fund, or asset management entity. Its business model centers on bringing gene therapies to market, not managing external capital.
What investment stages does Passage BIO target?
Passage BIO does not target investment stages. As a biotech developer, its activities range from pre-clinical research through clinical trials. The firm may seek partnerships or licensing deals for its pipeline, but it does not make investments in external companies.
Which sectors does Passage BIO explicitly avoid?
Public information does not specify sectors that Passage BIO avoids. Given its focus on gene therapies for rare diseases, the firm likely does not engage in fields like real estate, financial services, or technology outside its core therapeutic areas.
How does Passage BIO source proprietary deal flow?
As a biotech, Passage BIO generates its pipeline through internal R&D and potentially academic collaborations. It does not have deal flow in the investment sense. Public records do not detail specific sourcing mechanisms beyond standard biotech research partnerships.
Does Passage BIO maintain philanthropic structures?
There is no publicly available information confirming philanthropic structures associated with Passage BIO. The firm may have patient advocacy or foundation relationships, but these are not disclosed in accessible sources.
Where does the underlying wealth come from?
Passage BIO is a corporate entity, not a family office, so no underlying wealth origin applies. The company may have venture capital backing or public funding, but specific investors are not documented in this review.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: